TX-MAVENIR
16.4.2024 13:01:29 CEST | Business Wire | Press release
Mavenir, the cloud-native network infrastructure provider building the future of networks, today announces that the Mavenir Digital Enablement (MDE) is now available on Amazon Web Services (AWS) Marketplace.
Mavenir’s Digital Enablement (MDE) Business Support System (BSS) stack with composable architecture allows Communication Service Providers (CSPs) to implement innovative strategies and new selling models quickly, cost-effectively and with minimal risk, with the ability to test models iteratively and speed time-to-market without increasing capital and resource costs. MDE’s comprehensive set of modules already run on AWS – for reduced application-to-infrastructure test times – and span customer management, product catalog, order management, CRM, billing, converged charging, API monetization and network slice charging. With low-code/no-code visual builders and templated solutions-in-a-box, MDE is now available as a one-stop destination and digital marketplace for CSPs looking to implement new or complex models simply and agilely.
MDE offers a low-risk route to introducing profitable new business models such as split or sponsored billing, new package product offerings incorporating third-party solutions, automation for inter-partner manual tasks such as catalog mapping, and notifications mapping for service delivery to improve operational efficiency and the customer experience.
Mavenir’s Digital BSS has achieved platinum certification from TM Forum, with open APIs ensuring seamless integration with existing or new third-party systems and eliminating the need for resource-intensive system integration effort.
Sandeep Singh, Senior Vice President and General Manager for Mavenir’s Digital Business Enablement commented: “Mavenir’s Digital BSS is a transformative solution for service providers looking to stay ahead of the competition and launch innovative offerings in a fast time-to-market. Our arrival on AWS Marketplace is a strategic acceleration of our mission to drive sustainable global network automation and monetization, empowering the world’s operators to roll out advanced digital experiences at scale.”
He added: “By facilitating end-to-end digitization of customer interactions and streamlining collaboration with third-party partners – all within a stable and agile architecture – MDE Digital BSS provides service providers with a complete innovation framework to create seamless, personalized network service experiences for customers, and realize the gains with flexible monetization capabilities.”
John Abraham, Principal Analyst, Appledore Research noted: “One of the main innovation barriers for CSPs is the inflexibility of incumbent legacy BSS ecosystems, which require substantial investment in time, cost, and operational resources to enable new revenue models and service capabilities. Simplifying the path to the timely introduction of new business models and innovative best practices, as Mavenir is enabling with its MDE solution, provides CSPs with a distinct advantage in time to market and TCO.”
The MDE platform not only enables greenfield service providers to bring new services to market rapidly but also empowers brownfield service providers to modernize their legacy stack, accelerate digital transformation, and provides a viable path to migrate to 5G while co-existing with existing technologies (2G/3G/4G). MDE brings marketplace capabilities to service providers to cross sell 3rd Party Partner-led product and services integrated with CSPs and Mobile Virtual Network Operators (MVNOs) worldwide. The platform uses advanced AI-ML engines to derive intelligence from customer and network data, which is then used to recommend new products based on historical behavior, and also delivers categorization capabilities that enable service providers to fully capitalize on their rich datasets – bringing new revenues and boosting customer stickiness.
Notes to editors:
- More information about Mavenir’s Digital BSS:
https://www.mavenir.com/portfolio/mavapps/mavenir-digital-enablement-bss/
- Mavenir’s listing on AWS Marketplace:
https://aws.amazon.com/marketplace/pp/prodview-ylbqlsfj3bmay
About Mavenir:
Mavenir is building the future of networks today with cloud-native, AI-enabled solutions which are green by design, empowering operators to realize the benefits of 5G and achieve intelligent, automated, programmable networks. As the pioneer of Open RAN and a proven industry disruptor, Mavenir’s award-winning solutions are delivering automation and monetization across mobile networks globally, accelerating software network transformation for 300+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. For more information, please visit www.mavenir.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416395684/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 01:00:00 CEST | Press release
Expanded footprint advances the company’s global strategy in key growth region for healthcare and pharma brands Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Ka
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release
The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom